- Anavex Life Sciences press release ( NASDAQ: AVXL ): Q1 GAAP EPS of -$0.17 beats by $0.02 .
- Cash and cash equivalents of $143.6M.
- Shares -5.4% PM.
- CEO comment: “We look forward to presenting the complete dataset of the study as well as other long-term study data of the other programs, including Parkinson’s disease dementia and Rett syndrome. With a deep portfolio of promising therapies, we believe that Anavex remains well positioned to address the urgent needs of patients affected by neurodegenerative and rare neurodevelopmental diseases.”
For further details see:
Anavex Life Sciences GAAP EPS of -$0.17 beats by $0.02